Escalated Dose Proton Therapy Within the Multimodality Treatment of Glioblastoma Patients

Last updated: May 8, 2024
Sponsor: University of Aarhus
Overall Status: Active - Recruiting

Phase

N/A

Condition

Gliomas

Astrocytoma

Treatment

Escalated proton therapy

Clinical Study ID

NCT05768087
1-10-72-190-22
  • Ages > 18
  • All Genders

Study Summary

The goal of this phase 1 dose finding study is to to assess the clinical tolerability and safety of escalated dose proton therapy in glioblastoma patients treated with multimodality treatment, according to treatment volume.

The main questions it aims to answer are:

  • what is the maximum tolerated proton dose in glioblastoma patients?

  • is the maximum tolerated proton dose in glioblastoma patients dependent on treatment volume?

  • what is the recommended phase 2 proton dose in glioblastoma patients?

Patients will be asked to undergo radiotherapy to step-wise escalated doses using proton therapy as part of their multimodality treatment. Patients will be monitored closely for treatment effects.

Eligibility Criteria

Inclusion

Inclusion Criteria (main):

  • Newly diagnosed, contrast-enhancing GBM, IDHwt (WHO 2021 classification).
  • Maximal safe surgical resection is required; any extent of surgical resection isallowed (including biopsy-only).
  • Patient with target volume and location eligible for 60 Gy chemoradiotherapy.
  • Minimum distance between GTV and critical OAR (brainstem, chiasm, optic nerves andtracts in case of serviceable vision) of 5 mm on MRI-scan.
  • Age ≥ 18 years.
  • Karnofsky Performance Status grade of ≥ 70.
  • Adequate blood counts as assessed by treating physician.
  • Absence of any contraindication to undergo MRI and/or to receive Gadolinium contrastagent.
  • Before patient registration, written informed consent must be given according to GoodClinical Practice, and national/local regulations.

Exclusion

Exclusion Criteria:

  • All eligibility criteria are formulated as inclusion criteria.

Study Design

Total Participants: 36
Treatment Group(s): 1
Primary Treatment: Escalated proton therapy
Phase:
Study Start date:
April 15, 2024
Estimated Completion Date:
May 31, 2029

Study Description

This is a prospective, single-arm, phase 1 proton dose finding trial, aiming to assess the clinical tolerability and safety of escalated dose proton therapy (PT) in glioblastoma (GBM) patients, according to treatment volume. Radiotherapy will be administered with protons for the entire treatment, escalating the proton fraction-dose with the overall treatment time unchanged. The escalated proton dose will be prescribed to a subvolume of the radiation target. Escalated PT will be employed within the multimodality treatment; surgical procedures and concomitant and adjuvant chemotherapy follow the standard-of-care.

Patients will be subdivided in two groups based on the volume of the radiation target: patients with a CTV2 volume of <200 cc will be placed in group 1 and those with a volume ≥ 200 cc in group 2. Per group, proton dose will be escalated stepwise, which will be guided by a time to event continuous reassessment method (TiTE-CRM) to identify the MTD in this specific combination treatment.

The MTD in this trial is defined as the highest proton dose level at which no more than 30% of the patients develop dose limiting toxicities (DLTs) assessed up to 6 months after the start of PT.

Patient accrual to the main (dose escalation) part of the study ends when the MTD has been identified. If the statistically recommended MTD is declared, an expansion cohort to a total of 6 patients treated at the MTD and 6 patients at the MTD-1 (i.e. 1 dose level below MTD) will be considered. When all patients have been followed for toxicity for at least 1 year after the end of PT (and to a maximum of 2 years), the recommended phase 2 dose (RP2D) will be determined based on the full toxicity profile.

Connect with a study center

  • Aarhus University Hospital, Dept. of Oncology

    Aarhus, Central Denmark Region 8200
    Denmark

    Active - Recruiting

  • Danish Center for Particle Therapy

    Aarhus, 8200
    Denmark

    Site Not Available

  • Danish Centre for Particle Therapy

    Aarhus, 8200
    Denmark

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.